Traders assign a 92.5% implied probability to no new COVID variant of concern before 2027, reflecting the absence of any SARS-CoV-2 lineage meeting WHO or ECDC VOC criteria amid continued Omicron subvariant circulation. As of mid-2026, dominant strains such as XFG.1.1 and related lineages show steady but unremarkable spread, while monitored candidates like BA.3.2—first noted in late 2024 with notable spike mutations—have remained at low U.S. prevalence and have not produced increased severity or immune escape sufficient for escalation. Genomic surveillance through CDC and WHO systems continues without recent designations or rapid emergence signals, and updated 2026-2027 vaccines target prevailing JN.1 descendants. The short remaining timeframe to year-end further limits opportunities for a qualifying shift, consistent with the low historical rate of new VOCs in recent years.